Last updated October 9, 2026 · Originally published February 4, 2021
CBD and gum disease show up together constantly in marketing, but the research is messier than any bottle label suggests: lab studies cut in two directions at once, and the human evidence is thin — one small trial found a real benefit, but that’s one early result, not proof any specific CBD toothpaste or mouthwash treats gum disease.
What gum disease actually is
Gum disease starts as gingivitis — inflamed, sometimes bleeding gums from plaque buildup. Untreated, it can progress to periodontitis, where infection moves below the gumline and breaks down the bone and tissue holding teeth in place. It’s progressive but treatable: a dentist or periodontist can remove plaque and calculus below the gumline and bring the disease under control, and catching it early matters. Nothing below is a reason to delay that visit.
What the lab work shows
In lab studies, CBD is anti-inflammatory in cell culture and antibacterial. A 2021 study in Communications Biology found CBD active against a wide range of Gram-positive bacteria, including MRSA and VRSA, but largely inactive against Gram-negative bacteria, with a few exceptions. It also penetrated and killed cells inside established MRSA biofilms — the protective layer that helps bacteria resist antibiotics — and after 20 days of sublethal exposure, MRSA’s resistance barely moved (about 1.5-fold, versus 26-fold for a standard antibiotic tested the same way). This is laboratory work: it shows CBD can kill certain bacteria in a dish, not that a mouthwash clears an infection in your mouth. For more, see our antibacterial article. A smaller lab test found something similar directly on dental plaque: cannabinoids reduced bacterial colony counts more than two commercial toothpastes did. Its own title calls this “a preliminary observation” — an accurate description of what one culture-dish comparison can show. Most relevantly, the 2024 clinical trial discussed below also found that CBD inhibited Porphyromonas gingivalis, a bacterium associated with periodontitis, in a laboratory test.
Separately, a 2009 rat study found CBD injections reduced bone loss and inflammation in animals with ligature-induced gum disease — a rat study, not a human one, and not evidence of what an oral-care product does in a person’s mouth.
The complication: more CBD isn’t simply better
This is the part most CBD-and-oral-health articles leave out. A 2020 systematic review in Biomedicine & Pharmacotherapy included 29 studies testing CBD on normal, healthy human cells, including oral cells. The effect depended heavily on concentration: lower amounts often reduced inflammatory signaling, while higher amounts inhibited cell survival, growth, or movement — in oral-cell studies specifically, that inhibition generally appeared above 10 micromolar, across a range of differently designed experiments rather than one clean cutoff.
That figure is a lab-dish concentration, not a dose, and it can’t be validly converted into a safe or unsafe percentage for a toothpaste or mouthwash — how much CBD actually reaches and stays on oral tissue from a real product is a different question this review didn’t address. The review’s own conclusion was that CBD’s effects on healthy cells are dose- and time-dependent, with safe exposure levels still undefined. That ambiguity is the honest reading, not a reason to round up to “promising” or down to “harmful.”
The trial that was announced — and the one that actually ran
In 2019, Australian company Impression Healthcare announced a clinical trial of a CBD toothpaste and mouthwash using AXIM Biotechnologies’ products. Checking the actual registration (ACTRN12619000882123): it’s a Phase 2a trial for gingivitis, sponsored by Cannvalate, with a principal investigator at Swinburne University of Technology — a small Phase 2a trial that wouldn’t have settled the question on its own, even if it had run. The registry still lists it as “not yet recruiting,” with no results and no update since June 2019. Impression Healthcare was later renamed Incannex Healthcare; we found nothing under either name reporting results. It was announced in 2019, and we could not find evidence it ever started or reported anything.
A different, smaller trial did run and report results. A 2024 study in the Journal of Periodontal Research randomized 90 people with periodontitis to placebo, 1% CBD gel and toothpaste, or chlorhexidine gel with non-CBD toothpaste, for 56 days. Everyone first had professional plaque and calculus removal; the CBD group then used the toothpaste daily at home and had the gel professionally applied inside periodontal pockets three times over the trial — more intensive than simply brushing with a retail product. The CBD group improved significantly more than placebo on gum inflammation and bleeding, though a broader periodontal index didn’t change, and no adverse effects were reported. It’s a real double-blind, placebo-controlled trial — but the products came from a CBD company several researchers disclosed financial ties to, making independent replication especially important, and it tested professional in-office application of a specific 1% formulation, not an ordinary retail toothpaste used alone.
A smaller 2025 Polish pilot compared a rinse containing tea tree oil, CBD and spilanthol with tea tree oil alone in 40 people with gingivitis. The authors reported larger improvements in bleeding and plaque scores with the combination, but because CBD and spilanthol were added together, the study cannot show which ingredient — or whether the combination — was responsible. Beyond these two trials, we looked for other completed human trials of CBD oral-care products for gum disease and couldn’t find any.
What this means practically
There’s real lab evidence CBD can calm inflammation and kill relevant bacteria, a real dose-dependent caution about higher concentrations harming healthy cells, and one encouraging controlled trial plus one weaker pilot study suggesting a specific formulation might help. There’s no established CBD oral-care product, no established dose, and no large or independently replicated trial. Anything marketed as a CBD toothpaste or mouthwash for gum disease is ahead of the evidence.
On tooth sensitivity, a common marketing claim: we could not find any completed human study testing CBD for it. The closest is a registered trial of an experimental CBD gel for bleaching-related sensitivity, with no results posted yet. There’s currently no direct evidence either way.
Bottom line
Gum disease is progressive but treatable — a dentist, not a CBD product, is what actually treats it. Bleeding, swollen, or receding gums are worth a dental visit regardless of what else you try. The research here is genuinely active and partly encouraging, but it doesn’t yet support any specific product or replace periodontal care. For more on what CBD research does and doesn’t support, see our CBD research guide. This article is informational and isn’t medical advice.
